



IMRICOR Q4 FY23 QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C

HIGHLIGHTS:

- Secured approval to initiate the VISABL-AFL clinical trial at Johns Hopkins Hospital.
- Formally established a collaborative partnership with ADIS through the execution of a Joint Development Agreement. This strategic alliance focuses on seamlessly integrating state-of-the-art Artificial Intelligence (AI) modules developed by ADIS into Imricor's advanced NorthStar 3D mapping system.
- Expanded market presence by entering the Qatar market, facilitated by a distribution agreement with East Agency, WWL (East Agency).
- Attained Medical Device Marketing Authorization from the Saudi Food & Drug Authority, paving the way for commercialization efforts in the Kingdom of Saudi Arabia. Anticipate the first sale within six months.
- Letter of Intent received from the Pioneer Capital Fund to invest US\$8 million in Imricor in exchange for equity at a target price of US\$0.60 (A\$0.95) per share
- Consumable product revenues of US\$27,000 in Q4 2023, a 74% decrease quarter-on-quarter and an 46% decrease versus the prior corresponding periods ("pcp") reported basis. See European Sales Update below.
- As at 31 December 2023, Imricor had cash of approximately US\$0.8 million

30 January 2024 – Minneapolis, MN United States (**31 January 2024** – Melbourne, Australia) – **Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR)**, the global leader in real-time iCMR cardiac ablation products, today releases its Appendix 4C Quarterly Cash Flow Report for the period ended 31 December 2023 and provides an update on its operational performance.

Imricor's Chair and CEO, Steve Wedan, commented: "During the fourth quarter of 2023, we continued to build momentum toward a number of significant milestones, and some of those milestones have already come to fruition in January, as noted below in this briefing.

"As we look ahead, we believe 2024 will be the most exciting year in our Company's history. We expect consistent steady growth in procedure volume and consumable product revenue across Europe and the Middle East, and we will commence two global clinical trials, VISABL-VT and VISABL-AFL, to support expanded European indications and US FDA approval, respectively."

ADIS Joint Development Agreement

During the quarter, Imricor entered into a collaborative Joint Development Agreement (JDA) with ADIS SA, a leading company based in Lausanne, Switzerland. The partnership focuses on the integration of Artificial Intelligence (AI) modules developed by ADIS into Imricor's advanced NorthStar 3D mapping system. Specifically, the initial phase of collaboration aims to implement automatic segmentation of cardiac chambers from MRI images, a development anticipated to streamline time-consuming aspects of iCMR procedures. Additionally, the partnership extends to incorporating Imricor's NorthStar user interface into ADIS's ARTS iCMR procedure simulator platform. ARTS serves as a simulator platform enabling users to guide Imricor's Vision-MR Ablation Catheters within a physical tabletop device, providing a simulated view of the catheter's



location relative to real MRI-derived anatomy. The JDA sets the stage for the ARTS user environment to transition into the NorthStar user environment, showcasing a comprehensive collaboration between Imricor and ADIS in advancing cardiac mapping technology.

Middle East Expansion

Imricor has achieved significant milestones in market development, solidifying its presence in the Middle East. The company has entered into a 5-year Distribution Agreement with East Agency WWL, a prominent distributor in Qatar, granting exclusive rights for the distribution of Imricor's innovative iCMR family of ablation products in the country. In January, Imricor received Medical Device Marketing Authorization (MDMA) from the Saudi Food & Drug Authority, facilitating commercialization efforts in Saudi Arabia through its exclusive distributor, Al Faisaliah Medical Systems (FMS). FMS, with a strong track record and expansive distribution network, is positioned to propel Imricor's technology in a market where approximately 50,000 cardiac ablation procedures are conducted annually, aligned with the growth objectives of Saudi Vision 2030's Health Sector Transformation Program. These developments underscore Imricor's commitment to strategic market expansion and sustained growth.

VISABL-AFL Clinical Trial Update

In January, Imricor achieved a significant milestone with the approval of the VISABL-AFL clinical trial by Johns Hopkins Hospital's Institutional Review Board (IRB). The commencement of enrolment is anticipated in the coming weeks, marking a crucial step forward for the trial. VISABL-AFL holds paramount importance as it serves as the clinical trial pivotal to obtaining approval from the U.S. Food and Drug Administration (FDA) for Imricor's products.

European Sales Update

Consumable sales were down in the quarter, due to the normal holiday season, as well as the pausing of procedures at two key sites in the quarter. Maastricht UMC temporarily paused cases when informed that Philips no longer intended to commercialise their iSuite 3D mapping system. This pause is being resolved as Imricor and Phillips work together to make Imricor's NorthStar 3D mapping system function on the Philips MRI platform, removing the perceived dead end at Maastricht UMC. The Company expects procedures to resume at Maastricht in Q1 2024. Amsterdam UMC paused cases temporarily in the quarter to submit for Ethics Committee approval to perform a local clinical study with NorthStar, which is not yet a commercial product and therefore requires an Ethics-approved study at each site. Physicians at Amsterdam UMC are saving atrial flutter patients for the study. Approval for the study is expected in the coming weeks, and procedures will commence immediately.

Imricor's Chair and CEO, Steve Wedan, commented: "As I mentioned previously, our sales team was restructured to engage with each of our sites in the second half of 2023, with the goal of identifying and removing any roadblocks to consistent procedure volume. We believe these initiatives are yielding positive results, and we are already seeing consistency and growth in 2024."



Appendix 4C Cashflow for Q4 FY23

During the quarter ended 31 December 2023 (Q4 2023), Imricor reported net cash outflows from operating activities of US\$3.055 million. Receipts from customers during the period were US\$0.191 million comprising:

- equipment sales (US\$0.122 million);
- rental of capital equipment (US\$0.005 million); and
- consumable product sales (US\$0.063 million);

Payments made in relation to operating costs of US\$3.245 million were down compared to the prior quarter of US\$3.949 million primarily due to the payment of annual corporate insurance premiums during the prior period. When adjusted for these annual premiums, payments made during the prior period were US\$3.139 million. Compared to the adjusted amount, payments made in relation to operating costs during Q4 2023 increased approximately US\$0.106 million, or 3%.

Net cash outflows from investing activities were US\$0.010 million during the period.

Net cash inflows from financing activities were US\$2.523 million in the period, comprising net proceeds from the placement completed in October 2023.

At 31 December 2023, Imricor maintained a cash balance of US\$0.832 million. Payments made to related parties as described in Item 6.1 on the Appendix 4C were for directors' fees.

Imricor background

Imricor is leading the new field of *real-time iCMR cardiac ablations* – that is, cardiac ablations guided by real-time magnetic resonance imaging (MRI), rather than by conventional x-ray fluoroscopy. iCMR (*interventional cardiac magnetic resonance*) is the term used to describe such interventional procedures performed in conjunction with MRI. The goal is to provide faster, safer, and more effective treatments of cardiac arrhythmias compared to conventional means.

Imricor is the only company in the world that provides MRI-compatible consumable devices, such as single-use ablation catheters, required to perform cardiac ablations in an iCMR lab.

Benefits of real-time iCMR cardiac ablations are derived from the superior imaging capabilities of MRI compared to x-ray, especially when it comes to imaging the heart and vascular structures which are largely invisible to x-rays. Real-time iCMR also reduces repeated exposure to dangerous x-ray radiation.

Imricor's target market of cardiac ablations is estimated to be US\$8 billion worldwide.

Executing the VISABL-VT and VISABL-AFL trials, as well as re-establishing the iCMR-guided atrial flutter ablation market in Europe, post-pandemic, and expanding into new geographies like Australia, New Zealand, and the Middle East are key drivers of Imricor's growth.

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.



Media and Investor Relations Contact:

Simon Hinsley
simon@nwrcommunications.com.au
+61 401 909 653

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out real-time iCMR cardiac ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac ablation procedures.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also in the early stages of pursuing the required regulatory approvals to place its key products on the market in Australia and the U.S.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of



new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Imricor Medical Systems, Inc.

ABN

633 106 019

Quarter ended ("current quarter")

31 December 2023

Consolidated statement of cash flows	Current quarter \$USD'000	Year to date (12 months) \$USD'000
1. Cash flows from operating activities		
1.1 Receipts from customers	191	1,261
1.2 Payments for		
(a) research and development	(501)	(1,813)
(b) product manufacturing and operating costs	(332)	(1,172)
(c) advertising and marketing	(193)	(958)
(d) leased assets	-	-
(e) staff costs	(1,832)	(8,069)
(f) administration and corporate costs	(387)	(2,581)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	11	63
1.5 Interest and other costs of finance paid	(12)	(33)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	474
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(3,055)	(12,828)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	(77)
(d) investments	-	-
(e) intellectual property	(10)	(57)
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$USD'000	Year to date (12 months) \$USD'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant, and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(10)	(134)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	2,798	5,816
3.2	Proceeds from issue of convertible debt securities	-	2,675
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(58)	(162)
3.5	Proceeds from borrowings	-	631
3.6	Repayment of borrowings	(217)	(845)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	2,523	8,115

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	1,371	5,688
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,055)	(12,828)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(10)	(134)

Consolidated statement of cash flows		Current quarter \$USD'000	Year to date (12 months) \$USD'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	2,523	8,115
4.5	Effect of movement in exchange rates on cash held	3	(9)
4.6	Cash and cash equivalents at end of period	832	832

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$USD'000	Previous quarter \$USD'000
5.1	Bank balances	832	1,371
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	832	1,371

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

Current quarter \$USD'000
59
-

*Payments listed in 6.1 represent board fees

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

	Total facility amounts at quarter end \$USD'000	Amount drawn at quarter end \$USD'000
7.1 Loan facilities	1,500	33
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	1,500	33

7.5 **Unused financing facilities available at quarter end** 1,467

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Imricor was awarded a US\$1,500,000 loan through the North Dakota Commerce Department, the details of which were included in our announcement dated 22 December 2022. Imricor has full access to the funding subject to the use of funds limitations outlined on the Department of Commerce's LIFT program website.

8. Estimated cash available for future operating activities	\$USD'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(3,055)
8.2 Cash and cash equivalents at quarter end (item 4.6)	832
8.3 Unused finance facilities available at quarter end (item 7.5)	1,467
8.4 Total available funding (item 8.2 + item 8.3)	2,299
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	0.8

Note: if the entity has reported positive net operating cash flows in item 1.9 answer item 8.5 as 'N/A'. Otherwise, a figure for the estimated quarters of funding must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: The planned start of our clinical trials for ventricular tachycardia in Europe and atrial flutter in the United States may increase spending on research and development compared to the current period. Any significant decrease in future net operating cash outflows would be reliant upon future increases in receipts from customers.

- 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: Yes, Imricor has engaged with an Australia based investment bank to support the Company's planned equity raise to fund its operations and expects to announce further details by early February.

Additionally, Imricor continues to pursue an investment from the North Dakota Pioneer Capital Fund in accordance with the Letter of Intent to Invest received on 12 October 2023 (additional details included in the Cleansing Notice and Excluded Information announcement dated 25 October 2023).

Finally, the Security Subscription Facility Imricor secured from GEM Global Yield LLC SCS in July 2023 is available to provide cash of up to A\$29.6 million to fund operations (full details included in our announcements dated 6 July 2023 and 7 July 2023).

- 8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Yes, Imricor expects to continue its operations and to meet its business objectives based on its capital raising plans summarised in 8.6.2.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 about must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 31 January 2024

Authorised by: The Board

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g., Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and*

Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.